Arcutis reports positive topline data in Zoryve trial for infant AD

​Arcutis has reported positive topline data from the INTEGUMENT-INFANT Phase II trialassessing Zoryve cream 0.05% in infants aged three months to below 24 months with mild to moderate AD.

The post Arcutis reports positive topline data in Zoryve trial for infant AD appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.